Literature DB >> 7858928

Outpatient management of febrile episodes in neutropenic cancer patients.

E B Rubenstein1, K Rolston.   

Abstract

Febrile neutropenic patients have traditionally received hospital-based parenteral antibiotic therapy because of the risk of serious complications and associated mortality. Recently a low-risk subset among febrile neutropenic patients has been identified. Several alternatives to hospital-based therapy have been evaluated in such patients. These include early discharge to home antibiotic therapy after initial stabilization in the hospital, or treatment of the entire febrile episode with intravenous and/or oral antibiotics in an ambulatory setting. A multidisciplinary approach involving the physician and other health-care providers, the patients, and their families, ensures the success of this therapeutic modality. Careful patient selection, daily follow-up, close monitoring for the development of complications and/or adverse reactions, and informed consent along with detailed instructions to patients, minimize the risk of the development of serious complications. Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients should now be considered an acceptable alternative to hospital-based therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858928     DOI: 10.1007/bf00344049

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  8 in total

1.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

Review 2.  Controversies in the management of febrile neutropenic cancer patients.

Authors:  M Rubin; J W Hathorn; P A Pizzo
Journal:  Cancer Invest       Date:  1988       Impact factor: 2.176

3.  Beta-lactam regimens for the febrile neutropenic patient.

Authors:  G P Bodey; V Fainstein; L S Elting; E Anaissie; K Rolston; N Khardori; H Kantarjian; C Plager; W K Murphy; F Holmes
Journal:  Cancer       Date:  1990-01-01       Impact factor: 6.860

4.  The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation.

Authors:  J A Talcott; R Finberg; R J Mayer; L Goldman
Journal:  Arch Intern Med       Date:  1988-12

5.  Patterns of oropharyngeal and fecal flora in patients with acute leukemia.

Authors:  V Fainstein; V Rodriguez; M Turck; G Hermann; B Rosenbaum; G P Bodey
Journal:  J Infect Dis       Date:  1981-07       Impact factor: 5.226

6.  Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.

Authors:  E B Rubenstein; K Rolston; R S Benjamin; J Loewy; C Escalante; E Manzullo; P Hughes; B Moreland; A Fender; K Kennedy
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

7.  Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule.

Authors:  J A Talcott; A Whalen; J Clark; P P Rieker; R Finberg
Journal:  J Clin Oncol       Date:  1994-01       Impact factor: 44.544

8.  Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.

Authors:  J A Talcott; R D Siegel; R Finberg; L Goldman
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

  8 in total
  2 in total

1.  Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.

Authors:  James A Talcott; Beow Y Yeap; Jack A Clark; Robert D Siegel; Elizabeth Trice Loggers; Charles Lu; Paul A Godley
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

Review 2.  Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.

Authors:  F de Lalla
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.